Inetetamab

Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities[1][2].

Product Specifications

Product Name Alternative

CMAB-302; Cipterbin

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/inetetamab.html

Purity

96.54

Solubility

10 mM in DMSO

Smiles

[Inetetamab]

Molecular Weight

(145.1 kDa)

References & Citations

[1]Min Yan, et al. Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology. 2022. 40 (16), e13030-e13030. |[2]Deng L, et al. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. Open Life Sci. 2023 Jan 10;18 (1) :20220535.